OSF Healthcare Ventures contributed to a $102m series D round for Inflammatix, a developer of diagnostics systems for detecting infections.

US-based molecular diagnostics technology developer Inflammatix completed a $102m series D round yesterday that included OSF Healthcare Ventures, the investment arm of health system OSF Healthcare.

The round was led by investment firm D1 Capital Partners and also backed by Northpond Ventures, Khosla Ventures and Think.Health.

Inflammatix is working on rapid diagnostic tests that detect a patient’s immune response to infections by analysing mRNA biomarkers using machine learning technology.

The tests are able to identify whether an infection is viral…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn